In particular, 33 projects of Uzpharmsanoat were included to the list of the investment projects, which are under imlementation and prepared to realization in industry.

Total cost of these projects makes up US$390.4 million. At the same time, foreign investments and loans makes up US$319.4 million, loans of banks – US$51.1 million and own resources of Uzpharmsanoat – US$19.9 million.

Uzpharmsanoat will direct US$376.4 million to new construction and US$14 million to modernization and reconstruction.

In 2011-2015, it is planned to utilize investments for US$386.9 million. In the reporting period, the volume of invetsments to new construction will make up US$373.4 million and to modernization and reconstruction – US$13.5 million.

Main part of investments will be used within two projects. In particular, it is planned to organize production of immunobiologic medicmants in Tashkent by 2013. The annual capacity of the enterprise will make 12 million doses.

The cost of the project makes up US$100 million. The project is fully financed due to investments of Omninvest KFT (Hungary).

Diecon GmbH (Germany) will invest US$150 million to the project on production of insulina, injections and other medicaments in Tashkent region in 2011-2015. The plant will produce 25 million doses of medicaments a year.

The capacities on production of medicaments for treatment of socially important diseases will be created at Code Pharm in Navoi free industrial and economic zone. The enterprise will produce 468 million units of medicaments a year.

Poland’s Code Pharm Sp.z о.о. is planning to direct US$19.3 million to the project. The commercial banks will also allocate US$10 million.

Uzpharmsanoat also plans to launch production of syringes and needles, medicaments and injections, vitamins, antibiotics and others.

Twenty-one projects with the cost of US$348 million were included to new investment projects in industry, which are under development now. The volume of foreign investments to these projects will make up US$202.8 million, loans of the bank – US$145 million and own resources of Uzpharmsanoat – $0.2 million.

The volume of investments to new construction will make up US$327.5 million and to modernization and reconstruction – US$20.5 million.

Within these projects, it is planned to launch capacities on production of medicaments, anabolic medicaments, antiviral medicaments and others.

Uzpharmsanoat is also developing five perspective projects. The terms of four rojects, including its cost and capacities, are not defined yet. The cost of the fifth project is US$28 million. These projects will be directed to production of oncological medicaments, ferruginous medications, single use tests, etc.